Led by EXPERIENCED MANAGEMENT
Focused on discovery.
Leading Trends
Marvel is committed to providing maximum value to it’s shareholders while keeping a laser sharp focus on leading the way to new discoveries in science.
Leading Trends
Marvel is committed to providing maximum value to it’s shareholders while keeping a laser sharp focus on leading the way to new discoveries in science.
The A2a Receptor
The A2a receptor is a target for three diseases representing some of the areas of largest unmet medical need, each with multi-billion dollar potential.
The A2a Receptor
The A2a receptor is a target for three diseases representing some of the areas of largest unmet medical need, each with multi-billion dollar potential.
The Market
A valuable market, Marvel focus’ on 3 disease verticals totalling a combined potential value of over $200B.
The Market
A valuable market, Marvel focus’ on 3 disease verticals totalling a combined potential value of over $200B.
Focused on a Valuable Target.
The A2a receptor is a target for three diseases representing some of the areas of largest unmet medical need, each with multi-billion dollar potential.
- Neurological Diseases
- Cancer
The Marvel Model
Specifically focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. Marvel Biotechnology paves the way with a proven business model for taking synthetic chemical derivatives to market.
Neurological DiseasesCancer
Neurological Diseases
A $25B industry encompassing Depression and Anxiety, ADHD and Alzheimer’s Disease.
Marvel Biotechnology is focused on synthetic chemical derivatives of known drugs.
Cancer
A $170B industry encompassing many different facets.
Marvel Biotechnology is focused on synthetic chemical derivatives of known drugs.
Business and Compound Asset Strategy
Maximizing Capital
Marvel Biotechnology is committed to providing maximum value to it’s shareholders while maintaining a laser sharp focus on leading the way to new discoveries in science.
Operating with a proven model, Marvel leads the way in the optimization of synthetic chemical derivatives of known drugs.
- Private companies are eligible for SR&ED tax credits
- Will seek NSERC funding for cGMP synthesis of lead molecule (public or private companies eligible)
- Australia offers 43% refundable tax credit for research (public or private companies eligible)
Proven Players, Focused on True Discovery while Maximizing Capital.
0
+
Years of Experince
0
Proven Proprietary Compounds
0
Diseases Affected
0
B
Total Market Value